What's in Ionis Pharmaceuticals Incorporated (NASDAQ:IONS) After Decline in Shorted Shares?

Xavier Trudeau
Août 12, 2017

Akcea Therapeut has a 12-month low of $1.05 and a 12-month high of $16.30. (IONS) traded up 1.921% during midday trading on Friday, hitting $46.435. 2,627,979 shares of the stock were exchanged. The company has a 50 day moving average price of $53.06 and a 200-day moving average price of $46.75.

The company is trading up by 1.80 percent from yesterday's close.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, May 9th. In the last earnings report the EPS was $0.21 and is estimated to be $-0.02 for the current year with 123,987,000 shares presently outstanding. The firm had revenue of $110.30 million for the quarter, compared to the consensus estimate of $86.03 million. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. The business's revenue was up 199.2% on a year-over-year basis. Analysts expect next quarter's EPS will be $0.05 and the next full year EPS is anticipated to be $0.20.

Shares of Masonite International Corp (DOOR) have seen the needle move -1.63% or -0.95 in the most recent session.

ILLEGAL ACTIVITY NOTICE: This report was first posted by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another domain, it was illegally stolen and republished in violation of worldwide copyright legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/11/q3-2017-eps-estimates-for-ionis-pharmaceuticals-inc-nasdaqions-boosted-by-jefferies-group.html. Insiders sold 54,379 shares of company stock valued at $2,946,052 in the last three months. Parallel Advisors LLC raised its position in Ionis Pharmaceuticals by 62.8% in the second quarter. The value of the company's investment in Ionis Pharmaceuticals, Inc. increased from $13,104,000 to $17,414,000 a change of $4,310,000 quarter to quarter. Wellington Management Group LLP increased its stake in shares of Ionis Pharmaceuticals by 56.1% in the first quarter. FMR LLC increased its position in Ionis Pharmaceuticals by 2.1% in the first quarter. State Street Corp now owns 3,340,471 shares of the company's stock worth $134,285,000 after buying an additional 567,792 shares during the last quarter. Hanseatic Management Services Inc. purchased a new stake in shares of Ionis Pharmaceuticals during the first quarter valued at about $138,000. BB Biotech AG now owns 7,461,295 shares of the company's stock worth $299,944,000 after buying an additional 548,123 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Other equities research analysts have also issued reports about the company. Finally, Zacks Investment Research upgraded Ionis Pharmaceuticals from a hold rating to a buy rating and set a $58.00 target price for the company in a research note on Wednesday, July 12th. Stifel Nicolaus raised their target price on shares of Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a "hold" rating in a report on Wednesday. Finally, Leerink Swann reissued an "outperform" rating and set a $45.00 price target (down previously from $47.00) on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 17th. The stock of Ionis Pharmaceuticals Inc (NASDAQ:IONS) earned "Buy" rating by Laidlaw on Tuesday, December 27. They now have a $62.00 price target on the stock, up from their previous price target of $59.00. Ionis Pharmaceuticals has an average rating of "Hold" and an average target price of $47.13.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL